BRCA2 and cancer: Despite the rapid growth of next‐generation sequencing allowing for simultaneous testing of multiple genes linked to cancer risk, the clinical impact of pathogenic variants in genes beyond BRCA1 and BRCA2, especially in terms of CBC risk, is still largely unknown.